![]() AFFY 24 Dec 2014 Paid | Other | $0.05 Per Share |
8 May 2024 Date | | - Cons. EPS | - EPS |
28 Feb 2024 Date | | - Cons. EPS | - EPS |
27 Nov 2023 Date | | - Cons. EPS | - EPS |
20 Nov 2023 Date | | - Cons. EPS | - EPS |
13 Nov 2023 Date | | - Cons. EPS | - EPS |
![]() AFFY 24 Dec 2014 Paid | Other | $0.05 Per Share |
8 May 2024 Date | | - Cons. EPS | - EPS |
28 Feb 2024 Date | | - Cons. EPS | - EPS |
27 Nov 2023 Date | | - Cons. EPS | - EPS |
20 Nov 2023 Date | | - Cons. EPS | - EPS |
13 Nov 2023 Date | | - Cons. EPS | - EPS |
Biotechnology Industry | Healthcare Sector | Mr. Jonathan M. Couchman CFA CEO | OTC PINK Exchange | 00826A109 Cusip |
US Country | 2 Employees | 23 Dec 2014 Last Dividend | - Last Split | 15 Dec 2006 IPO Date |
Affymax, Inc. is a company with a history in the pharmaceutical industry that no longer has significant operational activities. Founded in 2001 and headquartered in New York, New York, Affymax was once engaged in the development of drugs aimed at improving the treatment of serious and often life-threatening conditions in the United States. However, it currently does not engage in any substantial operational activities, indicating a significant shift from its previous objectives in drug development.
Prior to its shift away from significant operations, Affymax, Inc. was involved in the following area: